创新链系列——中国创新药研发投入景气度指标2025年12月跟踪及全年总结

Investment Rating - The industry investment rating is "Positive" and maintained [10] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by abundant funds from A/H listings and capital increases of innovative drug companies. This is expected to improve the willingness to invest in R&D, leading to a new cycle of prosperity in the innovative drug industry [2][8][57]. Summary by Relevant Sections 2025 Prospective Indicator Trends - In December 2025, the IPO fundraising for pharmaceutical companies in Hong Kong reached 6.2 billion yuan, marking the second-highest monthly level since 2022. The A-share IPO fundraising for unprofitable companies opened up, with amounts of 4.2 billion and 2 billion yuan in October and December respectively [6][32]. - The fundraising scale for A-share pharmaceutical companies in December 2025 was 1.2 billion yuan, showing significant improvement year-on-year. The fundraising scale for Hong Kong pharmaceutical companies reached 13.9 billion HKD, the second-highest monthly level since 2022 [35]. - The total financing amount for China's biopharmaceutical sector in December 2025 was 1.23 billion USD, a new monthly high since 2022 [37]. - The upfront payment for external business development (BD) in Q4 2025 was 2.27 billion USD, with a record high of 1.5 billion USD in October [6][43]. 2025 Indicator Trends Summary - The total IPO fundraising for pharmaceutical companies in A-shares was 9.1 billion yuan in 2025, a year-on-year increase of 216.6%, while H-share IPO fundraising reached 33.6 billion yuan, up 334.7% [46]. - The fundraising scale for A-share pharmaceutical companies was 9.9 billion yuan, a year-on-year increase of 111.1%, and for H-share companies, it was 66.8 billion HKD, up 194.9% [54]. - The number of biopharmaceutical financing projects in China reached 201 in 2025, a year-on-year increase of 18.9%, with total financing amounting to 5.8 billion USD, up 28.0% [54]. - The upfront payment for external BD in 2025 was 6.9 billion USD, a year-on-year increase of 224.9%, with milestone payments reaching 125.98 billion USD, up 185.9% [54]. Overall Summary - The total amount of IPO fundraising, company capital increases, biopharmaceutical financing, and confirmed upfront payments for external BD in 2025 reached 201.5 billion yuan, a year-on-year increase of 145%. The funding levels for innovative drug companies significantly improved compared to 2024. Additionally, potential milestones for external BD reached 880.5 billion yuan, a year-on-year increase of 185.9% [8][50].